TrendRadars > News > Bluebird Bio Slips While FDA Lifts Partial Clinical Hold For Lovo-cel For Sickle Cell Disease
Bluebird Bio Slips While FDA Lifts Partial Clinical Hold For Lovo-cel For Sickle Cell Disease
Bluebird Bio Slips While FDA Lifts Partial Clinical Hold For Lovo-cel For Sickle Cell Disease,Bluebird Bio Slips While FDA Lifts Partial Clinical Hold For Lovo-cel For Sickle Cell Disease,bluebird bio, Inc. (BLUE) shares are declining more than 9 percent on Monday morning trade in spite of FDA lifting its partial clinical hold for patients under the age of 18 in the evaluation of lovotibeglogene autotemcel or lovo-cel for sickle cell disease.

Bluebird Bio Slips While FDA Lifts Partial Clinical Hold For Lovo-cel For Sickle Cell Disease

Bluebird Bio Slips While FDA Lifts Partial Clinical Hold For Lovo-cel For Sickle Cell Disease,bluebird bio, Inc. (BLUE) shares are declining more than 9 percent on Monday morning trade in spite of FDA lifting its partial clinical hold for patients under the age of 18 in the evaluation of lovotibeglogene autotemcel or lovo-cel for sickle cell disease.